Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPG302 in Amyotrophic Lateral Sclerosis
NCT06903286Phase 2Terminated
- Sponsor
- Spinogenix
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazbentetol in amyotrophic lateral sclerosis (ALS), sponsored by Spinogenix. Started May 2025; status: terminated.
02
Drugs
tazbentetol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06903286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903286.